You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

List of Excipients in Branded Drug XIFYRM


✉ Email this page to a colleague

« Back to Dashboard


Company Tradename Ingredient NDC Excipient Potential Generic Entry
Azurity Pharmaceuticals Inc XIFYRM meloxicam 24338-153 HYDROXYPROPYL BETADEX
Azurity Pharmaceuticals Inc XIFYRM meloxicam 24338-153 MEGLUMINE
Azurity Pharmaceuticals Inc XIFYRM meloxicam 24338-153 POVIDONE K12
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Excipient Strategy and Commercial Opportunities for XIFYRM

Last updated: March 2, 2026

What is the role of excipients in XIFYRM's formulation?

Excipients in XIFYRM serve multiple functions, including stability enhancement, bioavailability improvement, and patient compliance. Core excipients likely include binders, fillers, disintegrants, flow agents, and preservatives. Tailoring excipient selection affects manufacturing efficiency and pharmacokinetics.

How does excipient choice influence XIFYRM’s formulation development?

Selection impacts:

  • Stability: Excipient type impacts drug shelf life under various storage conditions.
  • Bioavailability: Certain excipients act as absorption enhancers or modifiers.
  • Manufacturing: Compatibility with active ingredients determines process scalability.
  • Patient experience: Flavoring agents, fillers, and disintegrants influence palatability and ease of administration.

What are current trends in excipient development relevant to XIFYRM?

Trends include:

  • Use of biocompatible excipients: Preference for GRAS (Generally Recognized As Safe) substances improves regulatory acceptance ([1]).
  • Opportunities in multifunctional excipients: Excipients offering combined functionalities reduce formulation complexity and costs.
  • Customization via excipient blends: Tailored excipient matrices optimize pharmacokinetics and patient acceptance.
  • Replacement of synthetic excipients: Natural and plant-based ingredients align with market preferences and regulatory shifts ([2]).

What are potential commercial opportunities based on excipient strategies?

  1. Formulation differentiation: Developing unique excipient combinations can enhance drug performance and patentability, enabling premium pricing.
  2. Regulatory advantage: Using well-established excipients expedites approval pathways, reducing time-to-market.
  3. Manufacturing cost efficiency: Selecting excipients that simplify processes reduces production costs, improving margins.
  4. Partnership and licensing: Collaborations with excipient manufacturers open channels for co-development, leveraging existing expertise.
  5. Market expansion: Formulations with improved stability and bioavailability appeal to emerging markets prioritizing simplified logistics and storage.

What regulatory considerations affect excipient choices for XIFYRM?

Excipients must be listed with acceptable use parameters in major regulatory agencies such as the FDA and EMA. Novel excipients require extensive safety data and can delay approval. Regulatory agencies increasingly favor excipients with well-documented safety profiles. Incorporating excipients approved in biowaivers or bioequivalence studies accelerates regulatory pathways.

How do patent strategies intersect with excipient selection?

Using innovative excipients or unique combinations can create patentable formulations, extending exclusivity. Patent filings must identify excipients and their functional role clearly. Strategic use of excipients can also fortify proprietary formulations against generics and facilitate licensing agreements.

What are the key challenges and risks in excipient selection?

  • Regulatory hurdles: Novel excipients face stringent approval timelines and requirements.
  • Compatibility issues: Excipient-active ingredient interactions can affect stability and efficacy.
  • Supply chain: Dependence on specific excipients introduces supply risks.
  • Cost implications: High-cost excipients reduce margins unless justified by formulation benefits.

Summary of strategic insights

Aspect Key Point Impact on Commercialization
Excipient Selection Focus on safety, regulatory status, and functionality Accelerates approval, reduces costs
Innovation Use multifunctional and natural excipients Differentiates product, increases market appeal
Cost and Supply Balance between performance and costs Ensures reliable production and margins
Intellectual Property Patented formulations with unique excipient combinations Extends market exclusivity

Key Takeaways

  • Excipient choice between formulation stability, bioavailability, and regulatory acceptance is critical for XIFYRM’s success.
  • Incorporate multifunctional, natural, and well-documented excipients to streamline development.
  • Strategic formulation design can unlock patent protection and competitive advantage.
  • Emphasize supply chain robustness and cost management in excipient planning.
  • Regulatory trends favor excipients with extensive safety data, reducing time-to-market.

FAQs

1. How do excipients influence drug stability?
Excipients affect drug stability by interacting chemically or physically with the active ingredient, either stabilizing it or promoting degradation. Proper selection minimizes moisture sensitivity, oxidation, or hydrolysis.

2. What excipients are most common in oral solid formulations like XIFYRM?
Common excipients include microcrystalline cellulose (filler/binder), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), and titanium dioxide (opacifier).

3. Can natural excipients replace synthetic ones?
Yes. Natural excipients such as starches, talc, or plant-derived carriers are increasingly used to meet market demand for natural products and regulatory preferences.

4. What is the impact of excipient patenting on product commercialization?
Patented excipients or unique combinations can extend market exclusivity. However, patentability depends on demonstrating novelty, non-obviousness, and functional advantage.

5. How does excipient compatibility influence manufacturing?
Incompatibility can cause instability, inconsistent dosages, or manufacturing delays. Compatibility testing ensures smooth scale-up and reliable product quality.


References

[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Safety Testing of Pharmaceutical Excipients. FDA.
[2] European Medicines Agency. (2021). Reflection Paper on Natural excipients in medicinal products. EMA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.